Ankara, Jul 11 (Prensa Latina) Turkey started testing with 39 patients from five hospitals the Cuban vaccine to fight lung cancer, Racotumomab, whose commercial name is Vaxira, T24 news website posted.
The drug came to the country with license from Argentina, its development was due to researchers from the Cuban Center of Molecular Immunology in collaboration with researchers from the University of Buenos Aires, and will be applied for an initial period of two or three months.
The main objective of the research is to observe in patients the autoimmune reaction the medicine tries to create in the human organism, like the other vaccines with viruses or bacteria do.
Unlike traditional treatments with chemotherapy and radiation, which attacks not only healthy but also cancerous cells, Racotumomab works by inducing the immune system to act against tumor tissues, blocking growth and slowing down its development, thereby increasing and improving the quality of life of the patient.
The therapy started in Turkey is a clinical trial, which will not continue for the moment because the vaccine is not registered in the country and is due to the efforts by oncologist, Nil Molinas Mandel, who after attending an international symposium held in Cuba last year sought some ways to prove it in Turkey.
Dr. Molinas stated that Turkish patients had been waiting for three years, since Racotumomab was registered in 2013.